Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAIL: Long-term safety and efficacy of Tecentriq in previously treated advanced NSCLC
2017-001409-34Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of atezolizumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Incidence of serious adverse events related to atezolizumab. Started Aug 2017; status: completed.
02
Drugs
atezolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2017-001409-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001409-34.